Journal: Molecular Therapy Oncology

Article Title: Engineered Salmonella -mediated c-di-AMP delivery activates STING to remodel the tumor microenvironment

doi: 10.1016/j.omton.2026.201185

Figure Lengend Snippet: Effect of SL disA therapy on T cells and macrophage from tumor samples (A, B) Flow Cytometry analysis of CD3 and CD8 surface markers(A) and CD3 + CD8 + cells statistical graph (B). (C, D) Flow cytometry analysis of CD3 and CD4 surface markers (C) and CD3 + CD4 + cells statistical graph (D). (E, F) Flow cytometry analysis of F4/80 and CD86 surface markers (E) and F4/80 + CD86 + cells statistical graph (F). Data are expressed as mean ± SEM, n = 3. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, one-way ANOVA with Tukey’s multiple comparisons tests.

Article Snippet: The following antibodies were used: FITC anti-mouse F4/80 (clone CI: A3-1), APC anti-mouse CD86 (clone GL-1), FITC anti-mouse CD3 (clone 17A2), APC anti-mouse CD4 (clone GK1.5), and APC anti-mouse CD8 (clone YTS-169), all purchased from Elabscience Biotechnology Co., Ltd.

Techniques: Flow Cytometry

Journal: Science Advances

Article Title: SRSF3 determines T reg cell fate in antitumor immunity and autoimmunity

doi: 10.1126/sciadv.aeh1671

Figure Lengend Snippet: ( A ) RNA splicing of human FOXP3 and mouse Foxp3 pre-mRNA. ( B ) Alignment of human FOXP3 (hFOXP3) and mouse Foxp3 (mFoxp3) exon 2 and nearby 50-bp intron sequences. ( C ) Mutations in mouse intron according to corresponding human sequences. Minigene plasmids were transfected into 293 cells. Exon 2 splicing was analyzed by RT-PCR. ( D ) A minigene system contains human genomic sequence from exon 1 to exon 3 of FOXP3 gene (wt). The corresponding sequence of mt4 was mutated to mouse sequence (mmt). Exon 2 splicing was analyzed by RT-PCR. ( E ) The Foxp3 humanized mouse (Foxp3-Hu) was generated by replacing C57BL/6N mouse Foxp3 exon 2 and adjacent 50-bp intron sequences with human corresponding sequences. ( F ) Foxp3 exon 2 skipping in Foxp3-Hu T reg cells was confirmed by RT-PCR and DNA sequencing. ( G ) Total FOXP3 (all-Foxp3) or full-length FOXP3 (full-Foxp3) expression in T reg cells was analyzed by flow cytometry. Full-length FOXP3 protein is recognized by FJK-16s antibody. Total FOXP3 protein is recognized by NRRF-30 antibody. The histograms showed quantification of T reg cells and the mean fluorescent intensity (MFI) of total FOXP3 or full-length FOXP3 ( n = 3). ( H to J ) A total of 0.5 × 10 5 MC38 cells were injected subcutaneously into left axilla of humanized or WT mice. Tumor sizes were measured every 2 to 3 days. * P < 0.05 and ** P < 0.01. [(I) and (J)] Mice were euthanized at day 28, and tumors were isolated and weighted. ( K and L ) A total of 2 × 10 5 MC38 cells were injected subcutaneously into humanized or WT mice. Mice were euthanized at the humane endpoints. ( L ) The intratumoral populations of CD4 + , CD8 + , or T reg cells were analyzed with flow cytometry. Histogram summarized amounts of intratumoral CD8 + and T reg cells and total FOXP3 MFI in T reg cells. Statistical significance was determined by an unpaired t test or a Mann-Whitney test. Survival analysis was performed with a log-rank test. n.s., not significant.

Article Snippet: Mouse cells were stained with eFluor 660–conjugated rat anti-mouse Foxp3 (FJK-16s; 50-5773-80; eBioscience, recognizing full-length Foxp3 protein), PE-conjugated rat anti-mouse Foxp3 (NRRF-30; 12-4771-82; eBioscience, recognizing all Foxp3 proteins), fluorescein isothiocyanate (FITC)–conjugated rat anti-mouse CD4 (RM4-5; 11-0042-85; Invitrogen), allophycocyanin (APC)-conjugated rat anti-mouse CD8a (53-6.7; 100711; BioLegend), Alexa Fluor 700–conjugated hamster anti-mouse TCRβ (H57-597; 109224; BioLegend), eFluor 660–conjugated rat IgG2a isotype antibody (eBR2a; 50-4321-82; eBioscience), FITC-conjugated rat IgG2a isotype antibody (eBR2a; 11-4321-82; eBioscience), Alexa Fluor 700–conjugated hamster IgG isotype (HTK888; 400926; BioLegend), APC-conjugated rat IgG2a isotype antibody (RTK2758; 400511; BioLegend), PE-conjugated rat IgG2a isotype antibody (eBR2a; 12-4321-80; eBioscience), APC-conjugated rat anti-mouse CD44 (IM7; 17-0441-81; eBioscience), APC-conjugated rat IgG2b isotype antibody (eB149/10H5; 17-4031-82; eBioscience), and PE-conjugated rat anti-mouse CD62L (MEL-14; 12-0621-81; eBioscience).

Techniques: Transfection, Reverse Transcription Polymerase Chain Reaction, Sequencing, Generated, DNA Sequencing, Expressing, Flow Cytometry, Injection, Isolation, MANN-WHITNEY

Journal: Science Advances

Article Title: SRSF3 determines T reg cell fate in antitumor immunity and autoimmunity

doi: 10.1126/sciadv.aeh1671

Figure Lengend Snippet: ( A to H ) Single cells were isolated from fresh cancer or adjacent normal tissues. Cells were labeled with anti-CD4 and anti-TCR antibodies, followed by intracellular anti-FOXP3 and anti-SRSF3 labeling. [(A) and (E)] Gating strategy to identify TCR + CD4 + FOXP3 + T reg cells and representative fluorescence-activated cell sorting (FACS) plots showing the expression levels of FOXP3 and SRSF3 in T reg cells isolated from oral squamous cell carcinoma (A) and breast cancer (E) or their adjacent normal tissues, respectively. [(B) and (F)] Summary of SRSF3-positive population percentage of T reg cells in oral squamous cell carcinoma (A) or breast cancer (E) tissues. [(C), (D), (G), and (H)] Summary of FOXP3 and SRSF3 MFI of T reg cells in oral squamous cell carcinoma [(C) and (D)] ( n = 5) or breast cancer [(G) and (H)] ( n = 8) tissues. Data are mean ± SEM. ( I ) Human T reg cells were purified from PBMCs and then transfected with siRNA [anti-SRSF3 or nonspecific (NS)]. PBMCs from the same donor were labeled by CFSE and mixed with T reg cells as the indicated ratio. Cells were cultured for 4 days in the presence of anti-human CD3 antibody (0.5 μg/ml). Then, cells were stained with an anti-CD8 antibody. The proliferation of CD8 + cells was measured by FACS. Data are mean ± SEM, n = 3. ( J ) Down-regulation of SRSF3 released the inhibition of T reg cell on the expression of TNF-α, IFN-γ, and IL-2 by CD8 + T cells. The expression levels of TNF-α, IFN-γ, and IL-2 in CD8 + T cells after in vitro suppression assay were analyzed by intracellular cytokine staining and FACS. Data are mean ± SEM, n = 5. P values are from a two-sided unpaired t test [(I) and (J)] or a paired t test [(B), (C), (D), (F), (G), and (H)].

Article Snippet: Mouse cells were stained with eFluor 660–conjugated rat anti-mouse Foxp3 (FJK-16s; 50-5773-80; eBioscience, recognizing full-length Foxp3 protein), PE-conjugated rat anti-mouse Foxp3 (NRRF-30; 12-4771-82; eBioscience, recognizing all Foxp3 proteins), fluorescein isothiocyanate (FITC)–conjugated rat anti-mouse CD4 (RM4-5; 11-0042-85; Invitrogen), allophycocyanin (APC)-conjugated rat anti-mouse CD8a (53-6.7; 100711; BioLegend), Alexa Fluor 700–conjugated hamster anti-mouse TCRβ (H57-597; 109224; BioLegend), eFluor 660–conjugated rat IgG2a isotype antibody (eBR2a; 50-4321-82; eBioscience), FITC-conjugated rat IgG2a isotype antibody (eBR2a; 11-4321-82; eBioscience), Alexa Fluor 700–conjugated hamster IgG isotype (HTK888; 400926; BioLegend), APC-conjugated rat IgG2a isotype antibody (RTK2758; 400511; BioLegend), PE-conjugated rat IgG2a isotype antibody (eBR2a; 12-4321-80; eBioscience), APC-conjugated rat anti-mouse CD44 (IM7; 17-0441-81; eBioscience), APC-conjugated rat IgG2b isotype antibody (eB149/10H5; 17-4031-82; eBioscience), and PE-conjugated rat anti-mouse CD62L (MEL-14; 12-0621-81; eBioscience).

Techniques: Isolation, Labeling, Fluorescence, FACS, Expressing, Purification, Transfection, Cell Culture, Staining, Inhibition, In Vitro, Suppression Assay

Journal: Science Advances

Article Title: SRSF3 determines T reg cell fate in antitumor immunity and autoimmunity

doi: 10.1126/sciadv.aeh1671

Figure Lengend Snippet: ( A ) Srsf3-flox mice were crossed with the Foxp3 YFP-cre mice to produce T reg cell–specific Srsf3-KO mice, including both Foxp3 YFP-Cre Srsf3 flox/flox homozygous (Srsf3-cKO) and Foxp3 YFP-cre Srsf3 flox/+ heterozygous (Srsf3 +/− ) KO mice. ( B ) Genotyping of Srsf3 gene KO in Srsf3-cKO mice. ( C ) T reg cells of Srsf3-cKO mice were isolated and checked for genomic deletion of Srsf3 gene by PCR (the presence of cleaved DNA fragment). CD8 + T cells were used as the non-KO control. WT are WT mice control. CD4 gene was used as DNA template control. ( D ) Srsf3-cKO and Srsf3 +/− mice at postnatal day 28. ( E ) Srsf3-cKO mice showed significant lower body weight than Srsf3 +/− mice at day 21. ( F ) Survival analysis of Srsf3-cKO and Srsf3 +/− mice. ( G ) FACS analyses of Srsf3 expression and population of T reg cells in the thymuses of Srsf3-cKO and Srsf3 +/− mice. ( H ) Serum anti-dsDNA antibody levels in Srsf3 cKO or Srsf3 +/− mice were analyzed by enzyme-linked immunosorbent assay. ( I ) Representative images (specimens and/or hematoxylin and eosin staining) of skin, thymus, spleen, lymph node, and liver from Srsf3-cKO and Srsf3 +/− mice. Histograms show thymus weight ( n = 4), spleen weight/body weight ( n = 4), and lymph node weight ( n = 4). Scale bar, 20 μm. ( J ) T reg cells in spleens or lymph nodes from Srsf3-cKO and Srsf3 +/− mice ( n = 4 or 5). ( K ) The expression levels of CD62L and CD44 in CD8 + T cells from the spleens or lymph nodes of Srsf3-cKO and Srsf3 +/− mice ( n = 3). Statistical significance was determined by a two-sided unpaired t test. Survival analysis was performed with a log-rank test.

Article Snippet: Mouse cells were stained with eFluor 660–conjugated rat anti-mouse Foxp3 (FJK-16s; 50-5773-80; eBioscience, recognizing full-length Foxp3 protein), PE-conjugated rat anti-mouse Foxp3 (NRRF-30; 12-4771-82; eBioscience, recognizing all Foxp3 proteins), fluorescein isothiocyanate (FITC)–conjugated rat anti-mouse CD4 (RM4-5; 11-0042-85; Invitrogen), allophycocyanin (APC)-conjugated rat anti-mouse CD8a (53-6.7; 100711; BioLegend), Alexa Fluor 700–conjugated hamster anti-mouse TCRβ (H57-597; 109224; BioLegend), eFluor 660–conjugated rat IgG2a isotype antibody (eBR2a; 50-4321-82; eBioscience), FITC-conjugated rat IgG2a isotype antibody (eBR2a; 11-4321-82; eBioscience), Alexa Fluor 700–conjugated hamster IgG isotype (HTK888; 400926; BioLegend), APC-conjugated rat IgG2a isotype antibody (RTK2758; 400511; BioLegend), PE-conjugated rat IgG2a isotype antibody (eBR2a; 12-4321-80; eBioscience), APC-conjugated rat anti-mouse CD44 (IM7; 17-0441-81; eBioscience), APC-conjugated rat IgG2b isotype antibody (eB149/10H5; 17-4031-82; eBioscience), and PE-conjugated rat anti-mouse CD62L (MEL-14; 12-0621-81; eBioscience).

Techniques: Isolation, Control, Expressing, Enzyme-linked Immunosorbent Assay, Staining

Journal: Dose-Response

Article Title: The Effects of Tibetan Medicine Renqing Changjue Extracts on Cyclophosphamide-Induced Immunosuppression in a Mouse Model

doi: 10.1177/15593258261454535

Figure Lengend Snippet: The effect of RQCJ on the proportion of CD4 + T and CD8 + T cells. (A) CD4 + /CD8 + T ratio in the different groups; (B-F) The flow cytometric analysis of CD4 + T and CD8 + T cells. Compared with the control group: ## p < 0.01. Compared with the CTX group: * p < 0.05, * * p < 0.01. (n = 12, one-way ANOVA was used for data analysis).

Article Snippet: We transferred 100 μL cell suspensions into flow cytometry tubes and added 10 μL of anti-mouse CD4 + T antibodies (FITC anti-mouse CD4, Clone: RM4-5, Concentration: 0.5 mg/mL) and CD8 + T antibodies (PE anti-mouse CD8a, Clone: 53-6.7, Concentration: 0.2 mg/mL) labeled with different fluorochromes (Dakewe, China).

Techniques: Control

Journal: Cancer Research

Article Title: Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression

doi: 10.1158/0008-5472.CAN-25-3092

Figure Lengend Snippet: IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and XBP1s levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.

Article Snippet: The antibodies used for flow cytometry: Brilliant Violet 605 anti-mouse CD127 (BioLegend, cat. #135025, RRID: AB_2562114, 5 μL/1 × 10 6 cells), FITC anti-mouse CD3 (BioLegend, cat. #100203, RRID: AB_312660, 2 μL/1 × 10 6 cells), APC anti-mouse CD3 (Elabscience, cat. #E-AB-F1013E, RRID: AB_3675272, 5 μL/1×10 6 cells), PE/Cyanine7 anti-mouse CD4 (Elabscience, cat. #E-AB-F1097H, 5 μL/1 × 10 6 cells), FITC Anti-Mouse CD8a (Elabscience, cat. #E-AB-F1104UC, 5 μL/1 × 10 6 cells), FITC anti-mouse CD19 (BioLegend, cat. #152403, RRID: AB_2629812, 0.25 μL/1 × 10 6 cells), FITC anti-mouse CD11c (BioLegend, cat. #117305, RRID: AB_313774, 0.5 μL/1 × 10 6 cells), FITC anti-mouse NK1.1 (BioLegend, cat. #108705, RRID: AB_313392, 0.5 μL/1 × 10 6 cells), Brilliant Violet 421 anti-mouse CD45 (BioLegend, cat. #103133, RRID: AB_10899570, 1 μL/1 × 10 6 cells), PE anti-mouse RORγt (BD Biosciences, cat. #562607, RRID: AB_11153137, 2 μL/1 × 10 6 cells), PerCP/Cyanine5.5 anti-mouse IL22 (BioLegend, cat. #516411, RRID: AB_2563373, 5 μL/1 × 10 6 cells), AF647 anti-STAT3 phospho (BioLegend, cat. #651007, RRID: AB_2572085, 5 μL/1 × 10 6 cells), PE anti-mouse CD45 (BioLegend, cat. #157604, RRID: AB_2876536, 1.25 μL/1 × 10 6 cells), APC anti-mouse CD8b (BioLegend, cat. #126613, RRID: AB_2562774, 0.625 μL/1 × 10 6 cells), APC anti-mouse CD4 (BioLegend, cat. #100411, RRID: AB_312696, 1.25 μL/1 × 10 6 cells), APC anti-mouse CD206 (BioLegend, cat. #141707, RRID: AB_10896057, 2.5 μL/1 × 10 6 cells), FITC anti-mouse F4/80 (BioLegend, cat. #157309, RRID: AB_2876535, 2 μL/1 × 10 6 cells), FITC anti-mouse CD25 (BioLegend, cat. #101907, RRID: AB_961210, 2 μL/1 × 10 6 cells), AF700 anti-mouse FOXP3 (BioLegend, cat. #126421, RRID: AB_2750492, 0.12 μL/1 × 10 6 cells), PE anti-mouse Ly6G (BioLegend, cat. #127607, RRID: AB_1186104, 1.25 μL/1 × 10 6 cells), APC anti-mouse CD274 (Elabscience, cat. #E-AB-F1132E, 5 μL/1 × 10 6 cells), PerCP-Cyanine5.5 anti–T-bet (eBioscience, cat. #45-5825-80, RRID: AB_953658, 0.25 μg/1 × 10 6 cells), PE/Dazzle 594 anti-mouse CD273 (BioLegend, cat. #107215, RRID: AB_2728124, 0.25 μg/1 × 10 6 cells), Brilliant Violet 421 anti-mouse CD274 (BioLegend, cat. #124315, RRID: AB_10897097, 5 μL/1 × 10 6 cells), and PE anti-mouse MHC-I (H-2Kk; BioLegend, cat. #114907, RRID: AB_313614, 0.25 μg/1 × 10 6 cells).

Techniques: Expressing, Control, Knockdown, RNA Sequencing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Binding Assay, Sequencing, Luciferase, Reporter Assay, Injection

Journal: Cancer Research

Article Title: Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression

doi: 10.1158/0008-5472.CAN-25-3092

Figure Lengend Snippet: Combination therapy enhances the anti–PD-L1 immunotherapeutic effect in gastric cancer. A and B, After tumor formation, the orthotopic gastric cancer mice ( n = 5 per group) were treated with anti–PD-L1 (100 μg per mouse), GPR34 inhibitor (20 mg/kg), or XBP1s inhibitor (30 mg/kg) every 3 days or ACh inhibitor (2.5 mg/kg) daily. Combinations of anti–PD-L1 with each inhibitor followed the every 3-day dosing schedule for a total duration of 2 weeks via i.p. injection. Living images were used to monitor tumor progression at 5-day intervals from the time of drug administration ( A ); IHC and mIF were performed to detect PD-L1 and XBP1s levels and proportions of CD4 + (green) and CD8 + (red) T cells in gastric cancer tissues at the end of treatments ( B ). Scale bars, 1.000e+5 –∼ 5.000e + 5 p/s/cm 2 /sr for living images; 200 μm for IHC; 50 μm for immunofluorescence. C and D, Representative images ( C ) and tumor volume ( D ) of subcutaneous tumors. The administration protocol for the mice was consistent with the description provided in A and B . **, P < 0.01; ***, P < 0.001.

Article Snippet: The antibodies used for flow cytometry: Brilliant Violet 605 anti-mouse CD127 (BioLegend, cat. #135025, RRID: AB_2562114, 5 μL/1 × 10 6 cells), FITC anti-mouse CD3 (BioLegend, cat. #100203, RRID: AB_312660, 2 μL/1 × 10 6 cells), APC anti-mouse CD3 (Elabscience, cat. #E-AB-F1013E, RRID: AB_3675272, 5 μL/1×10 6 cells), PE/Cyanine7 anti-mouse CD4 (Elabscience, cat. #E-AB-F1097H, 5 μL/1 × 10 6 cells), FITC Anti-Mouse CD8a (Elabscience, cat. #E-AB-F1104UC, 5 μL/1 × 10 6 cells), FITC anti-mouse CD19 (BioLegend, cat. #152403, RRID: AB_2629812, 0.25 μL/1 × 10 6 cells), FITC anti-mouse CD11c (BioLegend, cat. #117305, RRID: AB_313774, 0.5 μL/1 × 10 6 cells), FITC anti-mouse NK1.1 (BioLegend, cat. #108705, RRID: AB_313392, 0.5 μL/1 × 10 6 cells), Brilliant Violet 421 anti-mouse CD45 (BioLegend, cat. #103133, RRID: AB_10899570, 1 μL/1 × 10 6 cells), PE anti-mouse RORγt (BD Biosciences, cat. #562607, RRID: AB_11153137, 2 μL/1 × 10 6 cells), PerCP/Cyanine5.5 anti-mouse IL22 (BioLegend, cat. #516411, RRID: AB_2563373, 5 μL/1 × 10 6 cells), AF647 anti-STAT3 phospho (BioLegend, cat. #651007, RRID: AB_2572085, 5 μL/1 × 10 6 cells), PE anti-mouse CD45 (BioLegend, cat. #157604, RRID: AB_2876536, 1.25 μL/1 × 10 6 cells), APC anti-mouse CD8b (BioLegend, cat. #126613, RRID: AB_2562774, 0.625 μL/1 × 10 6 cells), APC anti-mouse CD4 (BioLegend, cat. #100411, RRID: AB_312696, 1.25 μL/1 × 10 6 cells), APC anti-mouse CD206 (BioLegend, cat. #141707, RRID: AB_10896057, 2.5 μL/1 × 10 6 cells), FITC anti-mouse F4/80 (BioLegend, cat. #157309, RRID: AB_2876535, 2 μL/1 × 10 6 cells), FITC anti-mouse CD25 (BioLegend, cat. #101907, RRID: AB_961210, 2 μL/1 × 10 6 cells), AF700 anti-mouse FOXP3 (BioLegend, cat. #126421, RRID: AB_2750492, 0.12 μL/1 × 10 6 cells), PE anti-mouse Ly6G (BioLegend, cat. #127607, RRID: AB_1186104, 1.25 μL/1 × 10 6 cells), APC anti-mouse CD274 (Elabscience, cat. #E-AB-F1132E, 5 μL/1 × 10 6 cells), PerCP-Cyanine5.5 anti–T-bet (eBioscience, cat. #45-5825-80, RRID: AB_953658, 0.25 μg/1 × 10 6 cells), PE/Dazzle 594 anti-mouse CD273 (BioLegend, cat. #107215, RRID: AB_2728124, 0.25 μg/1 × 10 6 cells), Brilliant Violet 421 anti-mouse CD274 (BioLegend, cat. #124315, RRID: AB_10897097, 5 μL/1 × 10 6 cells), and PE anti-mouse MHC-I (H-2Kk; BioLegend, cat. #114907, RRID: AB_313614, 0.25 μg/1 × 10 6 cells).

Techniques: Injection, Immunofluorescence